#401 The First Precision Medicine for Achondroplasia with Dr. Ravi Savarirayan
About this episode
This episode discusses the first precision medicine for achondroplasia, vosoritide, and the international guidelines for its treatment with Dr. Ravi Savarirayan.
Just a few years ago, there were no pharmacological treatments for patients with achondroplasia. Today, with multiple therapies on the market, the conversation has shifted from if we can treat to how we treat safely, consistently, and thoughtfully. In this third and final installment of our achondroplasia series, sponsored by BioMarin, we explore the recently published international consensus guidelines for vosoritide. These guidelines provide a roadmap for the entire treatment lifecycle, from the initial diagnosis and counseling to initiation, monitoring, and eventually, the transition off therapy. You can review the prescribing information for vosoritide here with additional safety information, including about the risk of low blood pressure. Joining us in-person all the way from Australia is the lead author of these guidelines, Dr. Ravi Savarirayan. Dr. Savarirayan is a global leader in skeletal dysplasia and has been a driving force in the clinical development of vosoritide from its earliest stages. Topics Discuss: The Journey of Vosoritide: Dr. Savarirayan shares his personal "why", from the early research phases to the clinical trials that changed the landscape of skeletal…
Sponsors
BioMarin
More episodes of DNA Today: A Genetics Podcast
- #403 Genetic Counseling Boards Prep: ABGC’s New Resources
- #402 How Genetic Genealogy Caught the Golden State Killer
- #400 The Story Behind "DNA Today"
- #399 How PKU Changed Newborn Screening Forever
Explore listener stats, chart rankings, contacts and more on the DNA Today: A Genetics Podcast podcast page.